A new point-of-care method for monitoring anti-platelet therapy: Application of the cone and plate(let) analyzer

Hebrew University of Jerusalem, Yerushalayim, Jerusalem, Israel
Platelets (Impact Factor: 2.98). 09/2005; 16(5):293-9. DOI: 10.1080/09537100400028800
Source: PubMed


Recent studies suggest that anti-platelet agents are not equally effective in all individuals. We have developed a new method to evaluate the effect of anti-platelet drugs using the cone and plate(let) analyzer (CPA) test. The method is based on the ability of activators to reduce platelet adhesion under flow conditions. Treatment of a blood sample with arachidonic acid (AA) or ADP in vitro significantly decreased platelet deposition to a surface coverage (SC) of 2.1+/-0.4 and 1.3+/-0.6%, respectively, compared with the basic SC of 12.3+/-6.8%. The effect of AA was prevented by aspirin (SC 8.1+/-3.8%) and that of ADP was reduced by 2-methylthio-AMP, a P2Y12 ADP receptor inhibitor (SC 4.8+/-2.0%). Pre-incubation with AA of whole blood samples from untreated healthy volunteers resulted in a marked decline of SC (from SC 9.8+/-2.2 to 0.6+/-0.3%). In contrast, in volunteers treated with 100, 300, and 500 mg aspirin per day, AA (but not ADP) decreased SC only to 3.5+/-1.3, 4.4+/-1.7, and 4.1+/-2.0%, respectively (P<0.001 versus SC with AA before treatment). A good correlation was observed between the modified CPA and aggregometry (R2=0.55). In conclusion, the modified CPA test is a useful tool to evaluate the efficacy of anti-platelet therapy.

6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Izvleček Izhodišča Bolniki z esencialno trombocitemijo (ET) imajo povečano število trombocitov v periferni krvi in pogosto tudi okvarjeno funkcijo trombocitov. Zapleti se pojavljajo v obliki tromboz ali krvavitev. Za preprečevanje tromboz bolniki pogosto profilaktično dobivajo acetilsali- cilno kislino (ASA). Danes je na voljo več načinov za oceno trombocitne funkcije, na pri- mer agregometrija in zapiralni čas. Mnogi izmed njih imajo številne pomanjkljivosti. V okviru raziskave smo skušali ovrednotiti nov način adhezije in agregacije trombocitov na polistirenski membrani (AAPM). Metode V raziskavo smo vključili 69 bolnikov z ET. Od tega je bilo 49 bolnikov, ki so prejemali ASA, in 20 bolnikov, ki niso prejemali ASA. Bolnikom smo izmerili agregacijo trombocitov z agregometrom, zapiralni čas ter preskušali funkcijo trombocitov z načinom AAPM. Izmer- jene vrednosti smo primerjali z vrednostmi zdravih oseb. Rezultati Pri bolnikih z ET v primerjavi z zdravimi osebami sta bila delež pokrite površine (1,7 % proti 3,3 %) in povprečna velikost trombocitov in trombocitnih agregatov (32 µm2 proti 45 µm2) prirejene preiskave AAPM statistično manjša (p < 0,05). Bolniki, ki so prejemali ASA, v primerjavi z bolniki, ki niso prejemali ASA, so imeli povečan delež pokrite površine (11 % proti 1,7 %), povprečno velikost trombocitov in trombocitnih agregatov (42 µm2 proti 32 µm2) in število trombocitov in trombocitnih agregatov (1421 proti 263) prirejene preiskave AAPM (p < 0,05). Zaključki Ugotovili smo, da je prirejena preiskava AAPM primerni način za določanja motenj funk- cije trombocitov pri bolnikih z ET. Poleg tega je prirejena preiskava AAPM primerna tudi za spremljanje učinka profilakse z ASA in za odkrivanje bolnikov z rezistenco na ASA. Ugotovili smo še, da številčna koncentracija trombocitov v krvi vpliva na število tromboci- tov in trombocitnih agregatov, izmerjenih s standardno preiskavo AAPM. Abstract Background People with essential thrombocythemia (ET) have increased number of circulating plate- lets. The function of platelets is often impaired. Some people with ET can suffer from ble- eding or clotting due to their disease. Acetylsalicylic acid (ASA) may be useful in treating patients with symptoms of microvascular occlusion. Numerous methods for evaluation of platelet function are available. Most of them have numerous disadvantages. In this rese- arch a new method adhesion and aggregation on polystyrene surface (AAPS) was asses- sed.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Percutaneous coronary intervention causes rupture of atherosclerotic plaque, which leads to platelet aggregation and thrombus formation. Antiplatelet and antithrombotic therapies are routine in the catheterization laboratory, but the optimal use of these agents during PCI continues to evolve. Central to the performance of procedures in the catheterization laboratory is the goal of decreasing ischemic complications while simultaneously minimizing bleeding complications. Dosing of medications for most disease processes involves some assessment of physiologic response to the medication. Despite the availability of multiple simple, point-of-care methods to monitor antiplatelet and anticoagulant therapies the utilization of these methods is almost never routinely performed and most anticoagulants are no longer monitored except for unfractionated heparin (UFH). As the use of more unique combinations of antithrombotic agents becomes commonplace, the need for effective monitoring will become even more important, making a thorough understanding of the limitations and benefits of present-day monitoring in the cath lab crucial.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Impact [cone and plate(let) analyzer (CPA) Technology]is testing whole blood platelet adhesion and aggregation under arterial flow conditions. The adhered platelets are stained and the percentage of surface covered (SC) by the stained objects and the average size (AS) of the objects are determined by image analyzer. The system allows screening of congenital primary hemostasis abnormalities, including adhesion as well as aggregation defects. The observation that exposure of blood to suboptimal concentrations of platelet agonists for 1 min prior to the Impact test causes platelet adhesion refractoriness led to the development of Impact aggregation tests and of specific tests for the determination of platelet response to aspirin and clopidogrel.
    Pathophysiology of Haemostasis and Thrombosis 02/2006; 35(1-2):83-8. DOI:10.1159/000093548 · 2.24 Impact Factor
Show more